Welcome to the Hologic Incorporated first quarter fiscal year 2010 earnings conference call. (Operator Instructions) I would now like to introduce Debra Gordon, Vice President of Investor Relations.

Good afternoon and thank you for joining us for Hologic’s first quarter fiscal year 2010 earnings conference call. I encourage everyone to visit the Hologic investor relations page of our website in order to view the PowerPoint presentation related to the comments that Glenn Muir, Hologic’s Chief Financial Officer will be making in his opening remarks. The replay of this conference call will be archived on our website. Please also note that a copy of the press release discussing our first quarter results as well as our second quarter and fiscal 2010 guidance is available in the investor relations section of our website under the heading Financial Results. Before we begin I would like to remind you of our Safe Harbor statement. Certain statements made by management of Hologic Inc. during the course of this conference call may be constitute forward-looking statements within the meanings of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Hologic to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include among others those detailed from time to time in the company’s filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to publicly release any updates or revision to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on any which any such statements are based. Also during the call, we will be discussing certain financial measures not prepared in accordance with generally accepted accounting principals or GAAP. A reconciliation of these non-GAAP financial measures to the related GAAP financial measures can be found in Hologic’s first quarter 2010 earnings release including the financial tables in the release. Please note that today’s conference call with consist of approximately 30 minutes of opening remarks from management followed by a 30 minute question and answer session. We therefore ask that each participant to limit his or her questions to just one with one follow up as necessary. I would now like to turn the call over to Mr. Robert Cascella, President and Chief Executive Officer.

Thank you Deb and good afternoon. Thank you for dialing in to our conference call. Joining me on the call is Glenn Muir, our Executive Vice President and CFO, Jack Cumming, our Chairman who is dialing in from China, Howard Duran, Head and Steve Williamson who was recently appointed to head our GYN Surgical group replacing Tony Kingsley. All of us will be available during the question and answer session. I’d like to take a minute to introduce Steve Williamson. Steve worked very closely with Tony in running all aspects of the Surgical business over the last several years and most recently led our GYN Surgical sales and marketing efforts as Vice President. Prior to this, Steve was part of Cytex sales and marketing group and came to that company through the acquisition of Novasec in 2004. As you can see, Steve is extremely familiar with all areas of the Surgical group and has been critical to the success of the business thus far. Our agenda for today’s call is as follows: I will review our business performance in the recently completed quarter and Glenn will discuss in more detail our first quarter financial results as well as provide our guidance for the second quarter and full year. We will then open up the call for Q&A. As Deb stated, we will conclude this call in about an hour. I’m extremely pleased to report that once again our quarterly revenues and adjusted earnings exceeded our guidance. I stated in our earnings release, Q1 2010 revenues were $412.4 million, a 3.9% decrease from Q1 of ’09 but up 2.4% sequentially from Q4 of ’09. This compared favorably to our guidance of $400 million to $405 million. While revenues were down year over year because we did not realize the full impact…

Thank you, Rob. As Rob stated, we are pleased with the revenue performance in each of our segments. Our mix of domestic and international product sales continues to be approximately 80% and 20%. Foreign currency translation had a modest positive impact on the reported revenue growth of less than 1% year over year, primarily within the Diagnostics and Surgical segments as most of these international sales are denominated in local currency. Turning to the rest of the P&L, our gross margin on a non-GAAP basis was 63%, up 140 basis points from the fourth quarter and up slightly versus 62.5% last year. This excluded $43.5 million of amortization of intangibles and is higher than our guidance range of 61% to 62%. The year over year improvement in gross margins was due primarily to product mix favoring higher margin disposable products and improved service margins. On a GAAP basis, gross margins were 52.5% versus the 51% to 52% we guided to. Our operating expenses on a non-GAAP basis of $130.4 million primarily excluding amortization, intangibles of approximately $13.6 million, came in above our fourth quarter non-GAAP expenses but within our guidance range of $130 million to $133 million. This expected increase from Q4 ’09 primarily resulted from increased sales and marketing expenses related to RX&A, our national sales meetings and new product launches. In the first quarter of fiscal 2010 the company adopted a new standard that changed the accounting for convertible debt instruments with cash settlement futures. The additional charge resulting from the adoption of this accounting guidance was $17.8 million this quarter and $16.5 million in the fourth quarter of last year. This non cash interest expense charge has been excluded from our non-GAAP results of operations for all periods presented. Absent the acquisition related and other charges, pre…

Thank you, Glenn. To wrap up, I too am once again extremely pleased with our results. We remain steadfast in our commitment to deliver the finest quality products in the world and uncompromising when it comes to exceeding customer expectations. All Hologic associates believe this to be our mission and I am convinced it remains our greatest differentiator in the marketplace. Lastly, I would be remiss if I did not emphasize that our longer term view on the growth prospects of our Hologic is optimistic given the strength of our technologies, our market leadership, the size of the addressable opportunities we serve and our strong financial position. This now concludes our opening remarks. We’ll be happy to answer any of your questions. Operator, please open up the call for Q&A.

(Operator Instructions) Your first question comes from Tycho Peterson – J.P. Morgan. Tycho Peterson – J.P. Morgan: Jumping into a question on the U.S. mammography market, is it your view that we’ve kind of hit a bottom on pricing and can you talk a little bit about your assumptions for pricing and then I know you don’t want to give unit numbers, but what it would take to get to the high and low end of the guidance throughout the course of the year.

I think that as we had talked about earlier, we think that the market stabilizing a bit, but it’s the demonstration which is the last two quarters and there are some anomalies. One quarter was our fourth quarter and the next was that it was the end of a calendar year and there was a lot of year end budget buying, so I think Q2 will be a good barometer in terms of understanding whether or not we really do have a trend, but we are certainly see good quarter activity, strong order activity. With that, I think relative to pricing we’re still penetrating the lower end of the market so ASP’s as a result of that product mix still have downward pressure but as I indicated in part of my talk, as we sell more product into the replacement market, our view is that they are fully configured Selenga’s or 2D dimensions products which will increase our mathematically calculated ASP, namely our ASP’s will start to nudge upward. We don’t see that as being significant this year but we do believe that the volume of it would be necessary in order to hit the higher end of our guidance. It has much more to do with the unit volume of the number of mammography systems sold versus a dramatic change in our ASP’s. Tycho Peterson – J.P. Morgan: On Cervista, can you provide us with an update on what the customer mix looks like today and what the reception has been to some of the automation introductions that you’ve talked about over the course of the year.

We continue to be very pleased with the progression both at the physician level as well as the lab. On our last call we had indicated that we believed the contracts we had signed up to date and customers that were live, if you projected that out on an annualized basis, we felt we were somewhere in the middle single digits from a market share perspective. We think we’re actually now more in the upper single digits so we continue to do well in the marketplace. Automation certainly is key, but there are a lot of other factors that determine when a customer goes on live. There’s obviously where they are on their current existing contract. Automation is a key contributor, but frankly if you ask me the reason most labs are taking a strong look at us and those who have made that choice, why they did so, it really again has to do with the advantages of the product. The existing competitor, when you go out at the OBGYN level, which again is the customer of the laboratory, one in ten results right now, they’re not getting the tests that they’re ordering. They’re either getting back a report of Q&S or they’re getting equivocal’s. And when you’re providing a service to the OBGYN, they would like to have an assay that has much lower Q&S rates and does not have that gray zone. So automation I know has continued to be a focus and we’re spending certainly a lot of time and dollars behind it and it is important. However, I think customer satisfaction of the end result is the most important, and that is why customers are switching to us. We are pleased with where we stand on our automation pathway but I think the folks that are choosing us are choosing us because they want to provide better customer satisfaction to the OBGYN and that’s why we continue to take share. Tycho Peterson – J.P. Morgan: With the organizational changes going on at FTA can you comment on your level of dialogue there and whether you feel like there’s at least stability here to build on?

There are ongoing conversations but they are with some of the new folks that have been assigned to the X-ray products, now part of the in-vitro diagnostic group. I think we’ll know much better over the next couple of months relative to how stable the organization is, but it is our hope with this latest round of changes in the FDA that we’ll have some consistent personalities that we’ll be dealing with over this next year.

Your next question comes from David Lewis – Morgan Stanley. David Lewis – Morgan Stanley: In your prepared remarks at the end you talked about the capital environment still remains somewhat less visible but on the recurring revenue side, which was 76% this quarter, the visibility should be much better. I wonder if you could share with us, given your optimism on new products, what is a realistic range of growth expectations that your recurring business can derive here over the long term, the next two to three years. Are we talking about a low single digit number, a mid single digit number or a high single digit number?

If I said yes to all of those it would be truthful. There is not one number. I think if you look at our expectations in NovaSure, we think that’s a significant market opportunity that is $1.5 billion to $2 billion in terms of the addressable market that has yet to be penetrated. We feel similarly about Cervista as well so when we look at those annuity businesses, we think it’s realistic to be in the low single digits. I think the other parts of our businesses that are more mature like our Diagnostic business, we’re happy with low single digit growth in that business and it happens to be a significant business. So on average it will pull the growth factors down on the company, but on our emerging opportunities we believe low single digits are most realistic. David Lewis – Morgan Stanley: If you think about the Diagnostic business in the quarter, if the Imager was strong internationally and international ThinPrep is still growing, and you’re up $5 million year over year, what’s the implication for what is going on with the U.S. business and can you update us on market share?

You’re talking about in Pac market share? David Lewis – Morgan Stanley: I’m just trying to figure out if the business is up $5 million, you had very strong trends in international Imager and international ThinPrep, it didn’t leave a lot of room for U.S. ThinPrep growth so I’m just wondering where share sits there.

We don’t think there’s been any real significant share shift over the last year to year an a half. I think what we have talked about particularly comparing 2008 to 2009, we definitely saw a softness in OBGYN visits for wellness, and we think we saw a fairly significant impact as we’ve talked about before between ’08 and ’09. We think that has stabilized so we think we’re probably market share neutral to where we were in 2008 and 2009. However, buying we do believe are slightly off as a result of the economy but it stabilized nicely over the last handful of quarters.

Your next question comes from Peter Bye – Jefferies & Company. Peter Bye – Jefferies & Company: A question on the Breast Health, you gave a couple of comments on the call but it’s a huge reversal from the last three quarter trend even though you continue to be down sequentially. Can you give us a little bit of color on why that number is so strong?

We saw some improvement in gross margins across the board but in particular in the Breast Health segment really as it related to our cost structure. We’ve been able to drive some cost out of the manufacturing side of the business especially as it relates to warranty costs on some of the detector, internally manufactured items. So I think our operations group is doing a terrific job of producing the product at the lowest possible point. Peter Bye – Jefferies & Company: Obviously then I guess it’s sustainable and it go down to the tax line. We had sort of 35% for the year. You’re talking about 36%. We might have been wrong on that one. Obviously we’re wrong on a lot of slots, but are you including the R&D tax credit in your tax rate and you’re thinking about more of an international business. Can you talk about that a little bit not only this year but maybe longer term trend without giving specific guidance?

As it relates to international, we don’t get a huge benefit there because we’re not manufacturing and selling. We’re really producing most of the product here in the States or in Costa Rica and transferring it back to the States, so we don’t get the same benefit of an international rate. Our international sales are still pretty low. As it relates to the R&D credit, that’s not reflected the full year but the first quarter.

Your next question comes from Amit Bhalla – Citi. Amit Bhalla – Citi: Also sticking along the lines of gross margin, while Breast was strong the Surgical gross margin when we adjust for amortization looks to be steadily dropping for the past several quarters. Can you address what’s happening on the Surgical side?

The Surgical side on margin is volume related. If we think back to the transfer of that product just about a year ago to the new facility in Costa Rico there was certainly start up and production costs we had to absorb. I don’t think we’re there yet. We’re certainly not at the type of absorption we think we can be at in the future especially as it relates to the start up of Adiana, but that’s being offset by greater improvements on the NovaSure side. So Surgical is another bright spot when we think about margins going forward. Amit Bhalla – Citi: Tomo, when do you think you will actually complete this assortment of trials that you’re doing and maybe you could comment on where we are today on the replacement market for 2D and where we should be by the end of the year.

We have not given specific dates in terms of FDA submissions but we are holding to an expected approval sometime in 2011; so with that, if we obviously back up there is going to be some submission either early 2011 or late in 2010. With respect with the second question was? Amit Bhalla – Citi: Replacement market 2D digital where are we today? Where should we be by the end of the year?

Right now it’s probably right around 5%. We think that will steadily grow but will still be in the single digits. I think that what we have talked about in the past that in order for us to normalize a replacement market which means it will be 10% to 15% of the install base, it’s probably 12 to 18 months out and that is our estimate.

Your next question comes from Thomas Kouchoukos – Stifel Nicolaus. Thomas Kouchoukos – Stifel Nicolaus: On the Breast biopsy business, could you give some color to the kind of magnitude of growth you’re seeing in this business? You held that one out as a grower this quarter. Then also maybe comment on the recent developments on the infringement case with J&J.

On the Breast biopsy front, with the exception of MammoSite which is part of that business unit, the business is growing somewhat fairly consistently somewhere between 15% and 20% a year. We don’t give our updates on any of our litigations so unfortunately I’ll have to defer on that. Thomas Kouchoukos – Stifel Nicolaus: Also the [Adivisa] business is one we don’t hear about too often anymore. Maybe comment on some of the success or where you are with expanding into that high risk market.

The high risk market as we’ve talked about on a couple of previous calls, it’s a little tougher sledding, changing the medical practice with that. I would still say that although we’ve made some progress the majority of the growth that we are seeing is still coming more from signs and symptoms. We’ve talked about it being heavy lifting on the at risk market but we continue to spend extra focus back in L&D and continue to make sure we’re getting signs and symptoms, although we are pleased with where we’re heading and we continue to see the product grow and we’re pleased with where it’s heading on a year over year basis.

Your next question comes from David for William Quirk – Piper Jaffray. David for William Quirk – Piper Jaffray: On Cervista, I’m curious if you could give us some color on the types of accounts that you’re adding, if they’re new accounts or if they’re repetitive ones.

The majority of those accounts are existing HPV users that are moving the business over to Cervista and they are not, obviously the national labs, but we have labs pretty much in every buying spectrum below that, so we have got a wide array of various laboratory sizes that have made the choice to come and do business with us. David for William Quirk – Piper Jaffray: I’m hoping you can give us an update on automated HPV instrument? Are the time lines still on track there and when do we anticipate launching in the U.S. and Europe?

We’re looking to summertime for a launch in the U.S. and probably slightly ahead of that in Europe.

Your next question comes from Jayson Bedford – Raymond James & Associates. Jayson Bedford – Raymond James & Associates: On Tomo, fiscal 2011 approval, does that assume a diagnostic label or a screening label?

We’re really going down a combined and dual path and it may be either or it may be both, and that would be the basis about it. But the elegance of the data that we’re presenting would support either indication so we are testing the words with the FDA in terms of what they are most likely to want to see relative to approval. We would guess that a diagnostic is probably a bit more manageable from their perspective but we also intend to have very strong and robust screening data. So without really having the FDA rule on something, our goal would be to have both diagnostic and screening and we believe the diagnostic may be first, but we have no real certainty from the FDA on that. Jayson Bedford – Raymond James & Associates: Tomo in Europe, how is that market unfolding? Are you seeing any type of competitive pressuring, pricing out there?

The only other company that is selling a Tomo product right now in Europe is Siemens and we’re not really seeing a lot of their sales activity. In the cases where they are in a competitive situation, they’re offering it up and they’re offering it up at a relatively low price, but I think much of that has to do with the product not really being ready yet, so they are fulfilling the desire or need on the customer’s part for a Tomo product but fully knowing that they have a way to go for that product to be clinically viable. So we are selling it to research and in the private sector and we’re selling the fully functioning product that we think is garnering some good clinical support.

Your next question comes from Isaac Ro – Leerink Swann. Isaac Ro – Leerink Swann: I think you mentioned at the beginning that Jack is over in China. I’m wondering if you can comment on that market and other emerging market opportunities for your business over the next 12 to 18 months.

We think that there are many markets, namely one as significant as China that represents good growth opportunities for us in the future. Right now it’s probably our second largest ThinPrep market, quickly becoming our largest, and in addition to that, we believe with the appropriate amount of infrastructure that we can also provide a digital mammography offering for that market to penetrate into the ultra low end. Those are things that we have not done thus far, but that’s clearly one of our intentions. So what we are looking at is their significance and building product in country and providing that as a basis to serve those local markets. But clearly it is an opportunity and it is an opportunity that is happening probably over the next three years. Isaac Ro – Leerink Swann: Looking in the Invader technology that may be past the current service HPVC, could you touch on what your expectations are for other pipeline products on that platform in the future?

We’re going to get down the path of something. We’ll have a CP&G offering and in terms of some of the other things that we’ll be focused on, it’s probably improving upon the current Cervista test more than even a string of other in-vitro diagnostics or electro-diagnostics. I think there’s a lot that we can improve upon; not just test results but the efficiency and work flow and that would probably be a resource drain as we look out the next three to five years.

Your next question comes from Amit Hazan – Oppenheimer. Amit Hazan – Oppenheimer: My first question is a clarification on the guidance. If I look at your new fiscal year 10 guidance versus what you just did in the first quarter. You beat the midpoint of your Q1 EPS by $0.04 but you’re raising guidance by $0.01. If you can clarify what’s going on there and why the bottom line raise is not going all the way through fiscal 10 guidance.

I think when we thing about, we were looking more at the year when we think about our guidance, and I appreciate that we did in fact beat guidance I think by $0.03 in Q1, and it’s not that it doesn’t translate into higher EPS for the full fiscal year, but rather we’re still in an early stage of looking at the full fiscal year and we’re trying to move the full fiscal year EPS needle forward, so we’re trying to rebalance the remainder of the three quarters. Amit Hazan – Oppenheimer: On the Diagnostics segment, if we look at things sequentially, your Diagnostic segment increased by less than $2 million and it’s pretty strong seasonality usually between the September quarter and the December quarter so I’m wondering with the growth that you outlined in some of the ramping up that you’re outlining in HPV, how we think about sequentially what happened in the quarter and why it may not have been even stronger.

I think as we reported in the summary, we had three things that really contributed and I’ll put them in ranking order. One is Cervista sales led, followed by unit volume internationally and then followed by Imager penetration. We have had a couple of quarters in the last five when we announced record ThinPrep volume sales worldwide. We had a very, very strong quarter; however it did not eclipse the highest quarter we’ve had. It was actually our second highest. So I think what we’re comparing is a unit volume that is not to its highest point that its been offset by three products that performed very favorably for the quarter.

Your next question comes from Vincent Ritchie – Wells Fargo Securities. Vincent Ritchie – Wells Fargo Securities: Considering all the discussion you’ve had with the FDA, there are two public meetings coming up this month where they’re discussing regulation and reclassification and the entire filing process for devices. I was curious as to your take on that and any concerns and/or things that might be positive coming out of that.

I still think there is ongoing discussions about the whole 510K process and with the delay of that as a filing alternative and whether the FDA, one of the discussions whether the FDA moves forward with the downgrading of digital mammography. Other than that, I don’t think we see anything coming out of the FDA that is going to be more onerous than it already is and in fact would welcome at least some definition out of the agency. So I think our comment is neutral to positive at this point. Vincent Ritchie – Wells Fargo Securities: You gave us an update on where you are with the term loan and will likely be through with that in the next couple of quarters. Can you remind us what your uses of cash are after that and also what the timeline is with the convert and the impact from that?

On the term loan, we’re expecting right now to have that paid off by the June quarter, so within the next two quarters. And beyond that the cash flow use for the remainder of the year is really to build up our cash balance. We really haven’t addressed the use of our capital allocation as we go into 2011, but we do recognize that that convert will come due in December 2013. The challenger there though it’s fairly low cost debt for us so we’re not rushing to pay it off.

Your next question comes from Sameer Harish – Needham & Company. Sameer Harish – Needham & Company: I wanted to clarify what you said about the market share in Cervista. Were you saying that the high single digit market share is based on the contracts that you have in hand or more projected contracts that you expect to have by the end of the fiscal year.

The contracts that we have in hand today, if you take them forward 12 months, the value of that revenue on an annuity basis over the next 12 months would take us to the high single digit market share which is the same calculation we did last quarter when we said it was in the mid. Sameer Harish – Needham & Company: In regards to the adoption of the automation or the semi-automation that you released recently, is that pretty ubiquitous across the labs that are looking to adopt service as a whole or is that still early?

The products were released at the end of the year so it is still very early on, and what I would say it has done, is continued to open more doors to have more meaningful conversations.

Your next question comes from Jonathan Block – Suntrust Robinson Humphrey Jonathan Block – Suntrust Robinson Humphrey: On NovaSure maybe you can address the growth rate there. It seems a little soft. I think constant currency for all of Surgical was just north of 4%. That was double digit last year and I’m assuming there’s a little bit there of Adiana. Maybe you could give some comments on what’s going on in the space specific to NovaSure.

When we look at the whole GYN market, we were actually very pleased with the performance we had in that space this quarter. We set revenue records both domestically as well as internationally and continue to have overall guidance for GSP of 12% to 15% growth for the year. So when we look at this space I think it’s an area we think we continue to take market share gains as well as assist in growing the market with this underserved market that’s out there by getting out to patients and doing what we can to drive those patients into a physician’s office. Jonathan Block – Suntrust Robinson Humphrey: It seems like more timing than anything else is what you’re saying.

Actually I would say the quarter was very strong for us. We did see record revenues as I said and I think that we’ll continue to see growth throughout the year. Jonathan Block – Suntrust Robinson Humphrey: And over to Breast Health that was well ahead of our estimate and may any commentary around market share between you and the other three players. We heard that maybe one of the guys stumbled for part of the quarter.

I don’t know if they stumbled. I think we stayed pretty steadfast relative to focusing on share and I think we’ve been running somewhere north of 60%. I think we’ve maintained or perhaps nudged a bit up on that. We are consistently winning on all of the deals that are being presented to us, so I am so sure that we are losing some that we aren’t aware of, but feel pretty confident that the product has been doing well and we are highly competitive at this point.

Your next question comes from Matthew Scalo – Canaccord Adams. Matthew Scalo – Canaccord Adams: I thought you mentioned you put plans in place to help penetrate the physician office with the NovaSure product. Are these new plans, additional headcount, just kind of incremental marketing spend on that side of things that differ from previous quarters that we should be aware of?

I think one of the things that we have been focused on is how do we assist in the Surgical Services side, namely anaestheology and we are looking at ways of support or partnering an anaestheologist and GYN surgeons really around the county, but we are watching very limited pilot programs in selected markets to test our hypothesis that that is a driver on further adoption and market growth. In markets where that growth has occurred naturally, our office penetration is double that of what the national average is. So we think that the test case would certainly give a strong indication that we want to continue and further that level of support. I don’t think it’s a tremendous amount of money for us to do it but it will invariably create, it will cause us to have to put some dollars to work. Our goal is to try to create reference centers around the United States. Matthew Scalo – Canaccord Adams: Switching gears to the MammoSite and now the launch, I know it was early September, probably had no impact on the quarter but what should we expect sequentially in this March quarter?

For MammoSite specifically, we’re looking at gaining back some market share incrementally over the course of this year. I don’t know what that specific numbers are given the newness of the product and our requirement for a lot of extensive training. The feedback has been excellent. I think it obviously meets all of the criteria necessary for both reimbursement and clinical adoption, but quite frankly it’s just a little early for us to tell at this point.

This concludes the question and answer session. I would like to turn the conference back over to Mr. Cascella for closing remarks.

Well, the wrap up, I once again am extremely pleased with everything that’s happened in the quarter. I really appreciate that everyone is joining in, all of the questions and with that we’ll end our call for this evening. Thank you very much.